Analyst Price Target is $40.00
▲ +12.42% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Roche in the last 3 months. The average price target is $40.00, with a high forecast of $40.00 and a low forecast of $40.00. The average price target represents a 12.42% upside from the last price of $35.58.
Current Consensus is
The current consensus among 10 polled investment analysts is to hold stock in Roche. This Hold consensus rating has held steady for over two years.
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, cardiovascular, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD); and strategic agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize zilebesiran. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.